August 10, 2021

Researcher Update: August 2021

In this month’s update, you’ll find information on:

CURE Epilepsy is Accepting Requests for Support for our Frontiers in Research Seminar Series Through August 13

CURE Epilepsy is accepting requests for research seminar support through August 13, 2021. The goal of CURE Epilepsy’s Frontiers in Research Seminar Series program is to expose researchers, clinicians, and students to exciting epilepsy research and provide opportunities for young investigators to interact with leaders in the field.

The Frontiers in Research Seminar Series is made possible through the generous support of the Nussenbaum-Vogelstein family.

Learn more and apply »

CURE Epilepsy is Accepting Applications for our COVID-19 Research Continuity Fund Through September 17

The CURE Epilepsy COVID-19 Research Continuity Fund will provide reimbursements of up to $15,000 for research-related expenses incurred as a result of institutional shutdowns during the pandemic and for which institutional support was not available or provided. This award is available to early-stage career investigators.

This program is made possible through a gift from the Cotton Family in honor of Vivian Cotton.


  • Request for Applications Open: Open Now!
  • End of Application Submission Period: Friday, September 17, 2021, 9pm ET

Learn more and apply »

ILAE COVID-19 and Epilepsy Award – New Submissions Open and Being Accepted Through August 31

ILAE is offering awards for COVID-19 and epilepsy projects, with one prize available per region. The ILAE COVID-19 and Epilepsy Research Award is for the best research focused on COVID-19 and epilepsy undertaken (published or in press) during the pandemic.

The award is open to all, and early career researchers are strongly encouraged to apply.

To be considered, please send your research reference (one article only is requested) and affiliation to Applications are due before August 31, 2021.

Check here to see the 2020 winners of the ILAE COVID-19 and Epilepsy Research Award.

Learn more »

Related News